Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection

Sarah K. Browne, Rifat Zaman, Elizabeth P. Sampaio, Kamonwan Jutivorakool, Lindsey B. Rosen, Li Ding, Minjal J. Pancholi, Lauren M. Yang, Debra Long Priel, Gulbu Uzel, Alexandra F. Freeman, Carlton E. Hayes, Roger Baxter, Stuart H Cohen, Steven M. Holland

Research output: Contribution to journalArticlepeer-review

106 Scopus citations


Patients with anti-IFN-γ autoantibodies have impaired IFN-7 signaling, leading to severe disseminated infections with intracellular pathogens, especially nontuberculous mycobacteria. Disease may be severe and progressive, despite aggressive treatment. To address the underlying pathogenic IFN-γ autoantibodies we used the therapeutic monoclonal rituximab (anti-CD20) to target patient B cells. All subjects received between 8 and 12 doses of rituximab within the first year to maintain disease remission. Subsequent doses were given for relapsed infection. We report 4 patients with refractory disease treated with rituximab who had clinical and laboratory evidence of therapeutic response as determined by clearance of infection, resolution of inflammation, reduction of anti-IFN-γ autoantibody levels, and improved IFN-7 signaling.

Original languageEnglish (US)
Pages (from-to)3933-3939
Number of pages7
Issue number17
StatePublished - Apr 19 2012

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology


Dive into the research topics of 'Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection'. Together they form a unique fingerprint.

Cite this